You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNitroprusside
Accession NumberDB00325  (APRD01143)
TypeSmall Molecule
GroupsApproved
DescriptionNitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency. [Wikipedia]
Structure
Thumb
Synonyms
[Fe(CN)5(NO)](2-)
Nitroferricyanide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NiprideSolution25 mgIntravenousHospira Healthcare Corporation2011-05-17Not applicableCanada
NipridePowder, for solution50 mgIntravenousHospira Healthcare Corporation1975-12-312011-08-05Canada
Sodium Nitroprusside for InjectionSolution25 mgIntravenousSterimax IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NitropressInjection, solution, concentrate50 mg/2mLIntravenousValeant Pharmaceuticals North America LLC2013-12-01Not applicableUs
NitropressInjection, solution, concentrate50 mg/2mLIntravenousHospira, Inc.1988-08-01Not applicableUs
NitropressInjection, solution, concentrate50 mg/2mLIntravenousMarathon Pharmaceuticals, LLC2013-12-012016-05-31Us
Sodium NitroprussideInjection, solution, concentrate25 mg/mLIntravenousSagent Pharmaceuticals2016-10-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sodium nitroprusside
ThumbNot applicableDBSALT000839
Categories
UNII169D1260KM
CAS number15078-28-1
WeightAverage: 215.938
Monoisotopic: 215.948300785
Chemical FormulaC5FeN6O
InChI KeyASPOIVQEUUCDQT-UHFFFAOYSA-N
InChI
InChI=1S/5CN.Fe.NO/c5*1-2;;1-2/q;;;;;2*-1
IUPAC Name
pentacyano(nitroso)irondiuide
SMILES
O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N
Pharmacology
IndicationFor immediate reduction of blood pressure of patients in hypertensive crises, reduce bleeding during surgery, and for the treatment of acute congestive heart failure
Structured Indications
PharmacodynamicsNitroprusside a powerful vasodilator relaxes the vascular smooth muscle and produce consequent dilatation of peripheral arteries and veins. Other smooth muscle (e.g., uterus, duodenum) is not affected. Sodium nitroprusside is more active on veins than on arteries.
Mechanism of actionOne molecule of sodium nitroprusside is metabolized by combination with hemoglobin to produce one molecule of cyanmethemoglobin and four CN- ions; methemoglobin, obtained from hemoglobin, can sequester cyanide as cyanmethemoglobin; thiosulfate reacts with cyanide to produce thiocyanate; thiocyanate is eliminated in the urine; cyanide not otherwise removed binds to cytochromes. Cyanide ion is normally found in serum; it is derived from dietary substrates and from tobacco smoke. Cyanide binds avidly (but reversibly) to ferric ion (Fe+++), most body stores of which are found in erythrocyte methemoglobin (metHgb) and in mitochondrial cytochromes. When CN is infused or generated within the bloodstream, essentially all of it is bound to methemoglobin until intraerythrocytic methemoglobin has been saturated. Once activated to NO, it activates guanylate cyclase in vascular smooth muscle and increases intracellular production of cGMP. cGMP stimulates calcium movement from the cytoplasm to the endoplasmic reticulum and reduces calcium available to bind with calmodulin. This eventually leads to vascular smooth muscle relaxation and vessel dilatation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Atrial natriuretic peptide receptor 1Proteinyes
agonist
HumanP16066 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Metabolized by reaction with hemoglobin to produce cyanmethemoglobin and cynide ions

SubstrateEnzymesProduct
Nitroprusside
Not Available
cyanmethemoglobinDetails
Route of eliminationOne molecule of sodium nitroprusside is metabolized by combination with hemoglobin to produce one molecule of cyanmethemoglobin and four CN¯ ions, thiosulfate reacts with cyanide to produce thiocyanate, thiocyanate is eliminated in the urine.
Half lifeApproximately 2 minutes
ClearanceNot Available
ToxicityOverdosage of nitroprusside can be manifested as excessive hypotension or cyanide toxicity or as thiocyanate toxicity. The acute intravenous mean lethal doses (LD50) of nitroprusside in rabbits, dogs, mice, and rats are 2.8, 5.0, 8.4, and 11.2 mg/kg, respectively.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nitroprusside.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroprusside.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nitroprusside.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Aliskiren.Approved, Investigational
AlprenololNitroprusside may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanNitroprusside may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineNitroprusside may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Nitroprusside.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nitroprusside.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Amphotericin B.Approved, Investigational
AmrinoneAmrinone may increase the hypotensive activities of Nitroprusside.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Nitroprusside.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Atenolol.Approved
AzelnidipineAzelnidipine may increase the hypotensive activities of Nitroprusside.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Azilsartan medoxomil.Approved
AzimilideAzimilide may increase the hypotensive activities of Nitroprusside.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Nitroprusside.Experimental
BarbitalBarbital may increase the hypotensive activities of Nitroprusside.Illicit
BarnidipineBarnidipine may increase the hypotensive activities of Nitroprusside.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bendroflumethiazide.Approved
BenidipineBenidipine may increase the hypotensive activities of Nitroprusside.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nitroprusside.Withdrawn
BepridilBepridil may increase the hypotensive activities of Nitroprusside.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nitroprusside.Approved
BethanidineBethanidine may increase the hypotensive activities of Nitroprusside.Approved
BimatoprostNitroprusside may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bortezomib.Approved, Investigational
BosentanNitroprusside may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nitroprusside.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bupivacaine.Approved, Investigational
BupranololNitroprusside may increase the hypotensive activities of Bupranolol.Approved
CaiCai may increase the hypotensive activities of Nitroprusside.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Candesartan.Approved
CandoxatrilNitroprusside may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nitroprusside.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Carvedilol.Approved, Investigational
CeliprololNitroprusside may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nitroprusside.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Cilazapril.Approved
CilnidipineCilnidipine may increase the hypotensive activities of Nitroprusside.Approved
CinnarizineCinnarizine may increase the hypotensive activities of Nitroprusside.Approved
ClevidipineClevidipine may increase the hypotensive activities of Nitroprusside.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Clonidine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Conivaptan.Approved, Investigational
CryptenamineNitroprusside may increase the hypotensive activities of Cryptenamine.Approved
CyclothiazideNitroprusside may increase the hypotensive activities of Cyclothiazide.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dapagliflozin.Approved
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Nitroprusside.Approved, Investigational
DarodipineDarodipine may increase the hypotensive activities of Nitroprusside.Experimental
DebrisoquinNitroprusside may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineNitroprusside may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nitroprusside.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Diclofenamide.Approved
DihydralazineNitroprusside may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Nitroprusside.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dipyridamole.Approved
DorzolamideNitroprusside may increase the hypotensive activities of Dorzolamide.Approved
DotarizineDotarizine may increase the hypotensive activities of Nitroprusside.Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Doxazosin.Approved
DuloxetineNitroprusside may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Nitroprusside.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Enalapril.Approved, Vet Approved
EnalaprilatNitroprusside may increase the hypotensive activities of Enalaprilat.Approved
EperisoneEperisone may increase the hypotensive activities of Nitroprusside.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Eplerenone.Approved
EpoprostenolNitroprusside may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitroprusside.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Etacrynic acid.Approved
FelodipineFelodipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
FendilineFendiline may increase the hypotensive activities of Nitroprusside.Withdrawn
FenoldopamNitroprusside may increase the hypotensive activities of Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Fimasartan.Approved
FlunarizineFlunarizine may increase the hypotensive activities of Nitroprusside.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Furosemide.Approved, Vet Approved
GabapentinGabapentin may increase the hypotensive activities of Nitroprusside.Approved, Investigational
GallopamilGallopamil may increase the hypotensive activities of Nitroprusside.Investigational
GuanabenzNitroprusside may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Nitroprusside.Approved
GuanethidineNitroprusside may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Halothane.Approved, Vet Approved
HexamethoniumNitroprusside may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Nitroprusside.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nitroprusside.Approved
HydralazineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideNitroprusside may increase the hypotensive activities of Hydroflumethiazide.Approved
IloprostIloprost may increase the hypotensive activities of Nitroprusside.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Indapamide.Approved
IndenololNitroprusside may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminNitroprusside may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nitroprusside.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nitroprusside.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nitroprusside.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Nitroprusside.Approved
KetanserinNitroprusside may increase the hypotensive activities of Ketanserin.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Labetalol.Approved
LacidipineLacidipine may increase the hypotensive activities of Nitroprusside.Approved
LamotrigineLamotrigine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
LatanoprostNitroprusside may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Levobupivacaine.Approved
LevodopaNitroprusside may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Lisinopril.Approved, Investigational
LofexidineNitroprusside may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Losartan.Approved
MacitentanNitroprusside may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Nitroprusside.Approved
MannitolThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nitroprusside.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Mecamylamine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nitroprusside.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitroprusside.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nitroprusside.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nitroprusside.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nitroprusside.Approved
MetipranololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nitroprusside.Approved, Investigational
MetyrosineNitroprusside may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Nitroprusside.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Nitroprusside.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Minoxidil.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nitroprusside.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nitroprusside.Approved
MorphineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Morphine.Approved, Investigational
MoxonidineNitroprusside may increase the hypotensive activities of Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nadolol.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Nitroprusside.Investigational
NebivololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Nitroprusside.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Nitroprusside.Approved
NicorandilNicorandil may increase the hypotensive activities of Nitroprusside.Approved
NifedipineNifedipine may increase the hypotensive activities of Nitroprusside.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Nitroprusside.Experimental
NiludipineNiludipine may increase the hypotensive activities of Nitroprusside.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Nitroprusside.Approved
NimesulideNimesulide may increase the hypotensive activities of Nitroprusside.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Nitroprusside.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Nitroprusside.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Nitroprusside.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nitroprusside.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nitroglycerin.Approved, Investigational
ObinutuzumabNitroprusside may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nitroprusside.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nitroprusside.Approved, Investigational
OmapatrilatNitroprusside may increase the hypotensive activities of Omapatrilat.Investigational
OxprenololNitroprusside may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Nitroprusside.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
PentoliniumNitroprusside may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nitroprusside.Approved, Investigational
PerhexilinePerhexiline may increase the hypotensive activities of Nitroprusside.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nitroprusside.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nitroprusside.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nitroprusside.Approved
PhenoxybenzamineNitroprusside may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nitroprusside.Withdrawn
PhentolamineNitroprusside may increase the hypotensive activities of Phentolamine.Approved
PinacidilNitroprusside may increase the hypotensive activities of Pinacidil.Withdrawn
PinaveriumPinaverium may increase the hypotensive activities of Nitroprusside.Approved
PindololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Nitroprusside.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nitroprusside.Withdrawn
PolythiazideNitroprusside may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Prazosin.Approved
PregabalinPregabalin may increase the hypotensive activities of Nitroprusside.Approved, Illicit, Investigational
PrenylaminePrenylamine may increase the hypotensive activities of Nitroprusside.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Prilocaine.Approved
PrimidonePrimidone may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Propranolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Nitroprusside.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nitroprusside.Approved
RasagilineRasagiline may increase the hypotensive activities of Nitroprusside.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nitroprusside.Approved
RescinnamineNitroprusside may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitroprusside.Approved
RilmenidineNitroprusside may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Riociguat.Approved
RisedronateRisedronate may increase the hypotensive activities of Nitroprusside.Approved, Investigational
RisperidoneNitroprusside may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabNitroprusside may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nitroprusside.Withdrawn
SaprisartanNitroprusside may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nitroprusside.Approved, Investigational, Vet Approved
SelexipagNitroprusside may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nitroprusside.Approved, Investigational
SitaxentanNitroprusside may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sotalol.Approved
SpiraprilNitroprusside may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sufentanil.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nitroprusside.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Telmisartan.Approved, Investigational
TemocaprilNitroprusside may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Terazosin.Approved
TerlipressinNitroprusside may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nitroprusside.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Thioridazine.Approved
TiboloneNitroprusside may increase the hypotensive activities of Tibolone.Approved
TicrynafenNitroprusside may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Tizanidine.Approved
TolazolineNitroprusside may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may increase the hypotensive activities of Nitroprusside.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Nitroprusside.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nitroprusside.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Trandolapril.Approved
TranilastTranilast may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitroprusside.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Nitroprusside.Approved
TravoprostTravoprost may increase the hypotensive activities of Nitroprusside.Approved
TreprostinilNitroprusside may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Triamterene.Approved
TrichlormethiazideNitroprusside may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinNitroprusside may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanNitroprusside may increase the hypotensive activities of Trimethaphan.Approved
UdenafilUdenafil may increase the antihypertensive activities of Nitroprusside.Approved, Investigational
UnoprostoneNitroprusside may increase the hypotensive activities of Unoprostone.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroprusside.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nitroprusside.Approved
VerapamilVerapamil may increase the hypotensive activities of Nitroprusside.Approved
VinpocetineVinpocetine may increase the hypotensive activities of Nitroprusside.Investigational
XylometazolineXylometazoline may increase the hypotensive activities of Nitroprusside.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nitroprusside.Approved, Vet Approved
ZiconotideZiconotide may increase the hypotensive activities of Nitroprusside.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC02DD01
AHFS Codes
  • 24:08.20
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (79 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8308
Blood Brain Barrier+0.9314
Caco-2 permeable-0.5269
P-glycoprotein substrateNon-substrate0.8966
P-glycoprotein inhibitor INon-inhibitor0.919
P-glycoprotein inhibitor IINon-inhibitor0.9767
Renal organic cation transporterNon-inhibitor0.9109
CYP450 2C9 substrateNon-substrate0.8573
CYP450 2D6 substrateNon-substrate0.8353
CYP450 3A4 substrateNon-substrate0.6675
CYP450 1A2 substrateNon-inhibitor0.6719
CYP450 2C9 inhibitorNon-inhibitor0.8599
CYP450 2D6 inhibitorNon-inhibitor0.9186
CYP450 2C19 inhibitorNon-inhibitor0.8218
CYP450 3A4 inhibitorNon-inhibitor0.9763
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9583
Ames testNon AMES toxic0.5204
CarcinogenicityCarcinogens 0.6595
BiodegradationNot ready biodegradable0.5759
Rat acute toxicity2.9543 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9345
hERG inhibition (predictor II)Non-inhibitor0.9596
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Abbott laboratories
  • Abbott laboratories pharmaceutical products div
  • Hospira inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous50 mg
SolutionIntravenous25 mg
Injection, solution, concentrateIntravenous50 mg/2mL
Injection, solution, concentrateIntravenous25 mg/mL
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP0.071ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area148.38 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity39.44 m3·mol-1ChemAxon
Polarizability16.52 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as organic metal salts. These are organic salt compounds containing a metal atom in its ionic form.
KingdomOrganic compounds
Super ClassOrganic salts
ClassOrganic metal salts
Sub ClassNot Available
Direct ParentOrganic metal salts
Alternative Parents
Substituents
  • Organic metal salt
  • Organic cyanide salt
  • Hydrocarbon derivative
  • Organic transition metal salt
  • Organonitrogen compound
  • Organometallic compound
  • Organic transition metal moeity
  • Organic anion
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein kinase activity
Specific Function:
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
Gene Name:
NPR1
Uniprot ID:
P16066
Molecular Weight:
118918.11 Da
References
  1. Fortin Y, De Lean A: Role of cyclic GMP and calcineurin in homologous and heterologous desensitization of natriuretic peptide receptor-A. Can J Physiol Pharmacol. 2006 May;84(5):539-46. [PubMed:16902599 ]
  2. Madhani M, Okorie M, Hobbs AJ, MacAllister RJ: Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo. Br J Pharmacol. 2006 Nov;149(6):797-801. Epub 2006 Oct 3. [PubMed:17016498 ]
  3. Steinmetz M, Potthast R, Sabrane K, Kuhn M: Diverging vasorelaxing effects of C-type natriuretic peptide in renal resistance arteries and aortas of GC-A-deficient mice. Regul Pept. 2004 Jun 15;119(1-2):31-7. [PubMed:15093694 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23